JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

Search

AbbVie Inc

Geschlossen

BrancheGesundheitswesen

198.07 -0.35

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

198

Max

198.64

Schlüsselkennzahlen

By Trading Economics

Einkommen

1.3B

1.3B

Verkäufe

2.1B

15B

KGV

Branchendurchschnitt

92.578

34.393

EPS

2.97

Dividendenrendite

3.31

Gewinnspanne

9.66

Angestellte

55,000

EBITDA

-4.3B

117M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+9.3% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

3.31%

2.54%

Nächstes Ergebnis

29. Okt. 2025

Nächste Dividendenausschüttung

15. Aug. 2025

Nächstes Ex-Dividendendatum

14. Okt. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

12B

348B

Vorheriger Eröffnungskurs

198.42

Vorheriger Schlusskurs

198.07

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

AbbVie Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

31. Juli 2025, 12:46 UTC

Ergebnisse

AbbVie 2Q Results Top Wall Street's Forecasts with Boost from Skyrizi, Rinvoq Sales

30. Juni 2025, 13:02 UTC

Akquisitionen, Fusionen, Übernahmen

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion in Cash

25. Apr. 2025, 13:57 UTC

Ergebnisse

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised -- Update

25. Apr. 2025, 12:52 UTC

Ergebnisse

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised

31. Juli 2025, 12:08 UTC

Ergebnisse

AbbVie Stock Pops After Earnings Beat and Guidance Raised -- Barrons.com

31. Juli 2025, 11:46 UTC

Ergebnisse

AbbVie Raises FY Outlook

31. Juli 2025, 11:44 UTC

Ergebnisse

AbbVie 2Q Global Net Rev From Oncology Portfolio $1.68B >ABBV

31. Juli 2025, 11:44 UTC

Ergebnisse

AbbVie 2Q Global IMBRUVICA Rev $754M >ABBV

31. Juli 2025, 11:44 UTC

Ergebnisse

AbbVie 2Q Global Skyrizi Rev $4.42B >ABBV

31. Juli 2025, 11:44 UTC

Ergebnisse

AbbVie 2Q Adj EPS $2.97 >ABBV

31. Juli 2025, 11:44 UTC

Ergebnisse

AbbVie 2Q U.S. HUMIRA Rev $802M >ABBV

31. Juli 2025, 11:44 UTC

Ergebnisse

AbbVie Sees FY Adj EPS $11.88-Adj EPS $12.08 >ABBV

31. Juli 2025, 11:44 UTC

Ergebnisse

AbbVie 2Q EPS 52c >ABBV

31. Juli 2025, 11:44 UTC

Ergebnisse

AbbVie 2Q Rev $15.42B >ABBV

31. Juli 2025, 11:44 UTC

Ergebnisse

AbbVie 2Q International HUMIRA Rev $378M >ABBV

31. Juli 2025, 11:44 UTC

Ergebnisse

AbbVie 2Q Net $938M >ABBV

30. Juni 2025, 12:47 UTC

Akquisitionen, Fusionen, Übernahmen

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1B in Cash

30. Juni 2025, 12:33 UTC

Akquisitionen, Fusionen, Übernahmen

AbbVie Will Acquire Capstan, Including CPTX2309, a Potential First-In-Class in Vivo tLNP anti-CD19 CAR-T Therapy Candidate >ABBV

30. Juni 2025, 12:33 UTC

Akquisitionen, Fusionen, Übernahmen

AbbVie : Proposed Acquisition Strengthens Commitment to Transforming Patient Care With Capstan's Innovative tLNP Platform Technology >ABBV

30. Juni 2025, 12:32 UTC

Akquisitionen, Fusionen, Übernahmen

AbbVie Will Pay Up to $2.1B in Cash at Closing to Acquire Capstan >ABBV

30. Juni 2025, 12:31 UTC

Akquisitionen, Fusionen, Übernahmen

AbbVie To Acquire Capstan Therapeutics, Further Strengthening Commitment To Transforming Patient Care In Immunology >ABBV

7. Mai 2025, 09:30 UTC

Top News

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

28. Apr. 2025, 12:44 UTC

Ergebnisse

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

28. Apr. 2025, 09:33 UTC

Ergebnisse

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25. Apr. 2025, 16:03 UTC

Ergebnisse

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25. Apr. 2025, 14:00 UTC

Top News
Ergebnisse

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25. Apr. 2025, 12:24 UTC

Top News
Ergebnisse

AbbVie Stock Jumps as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25. Apr. 2025, 12:03 UTC

Top News
Ergebnisse

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25. Apr. 2025, 11:43 UTC

Ergebnisse

AbbVie 1Q U.S. HUMIRA Rev $744M >ABBV

25. Apr. 2025, 11:43 UTC

Ergebnisse

AbbVie 1Q International HUMIRA Rev $377M >ABBV

Peer-Vergleich

Kursveränderung

AbbVie Inc Prognose

Kursziel

By TipRanks

9.3% Vorteil

12-Monats-Prognose

Durchschnitt 216.47 USD  9.3%

Hoch 255 USD

Tief 170 USD

Basierend auf 17 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für AbbVie Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

17 ratings

11

Buy

6

Halten

0

Sell

Technischer Score

By Trading Central

180.37 / 195.54Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.